Oral pemphigoid autoantibodies preferentially target BP180 ectodomain

Calabresi, Valentina; Carrozzo, Marco; Cozzani, Emanuele; Arduino, Paolo Giacomo; Bertolusso, Giorgio; Tirone, Federico; Parodi, Aurora; Zambruno, Giovanna; Zenzo, Giovanni Di

doi:10.1016/j.clim.2006.10.007

Cited by 55 publications

(55 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major proteins that exist in the hemidesmosome are the transmembrane proteins, cytoplasmic adapter proteins and cytoskeletal filaments. These proteins along with the laminin 332 protein is what will attach to the basal layer and will aid to form the adhesion complex found specifically in blistering autoimmune diseases [21]. The hemidesmosome is then used to observe the detachment of the epithelium from the connective tissue.…”

Section: Immunohistochemistry and Related Malignancy Of Antilaminin 332mentioning

confidence: 99%

Mucous membrane pemphigoid: A wide-ranging assessment of various cases and corresponding methods of diagnosis and treatment

Sivri¹,

Chandra²

2018

Med-Science

View full text Add to dashboard Cite

Mucous Membrane Pemphigoid (MMP) is as an infrequent yet tenacious autoimmune blistering disease involving the mucosae of the oral cavity, as well as the conjunctiva, genitals, nasal cavity, pharynx and occasionally the skin. It is seen most commonly in older adults, although cases have been reported throughout early childhood. This review article will provide a thorough explanation of MMP by discussing common misdiagnosis scenarios, presenting rare case reports, and exploring recent treatment options in hopes of spreading awareness for furthering research on diagnosis techniques. The purpose this article is to bring light to the dental community, medical professionals and autoimmune disease researchers, the importance of an early and authentic diagnosis and corresponding methods of recent treatments.

show abstract

Section: Immunohistochemistry and Related Malignancy Of Antilaminin 332mentioning

confidence: 99%

Mucous membrane pemphigoid: A wide-ranging assessment of various cases and corresponding methods of diagnosis and treatment

Sivri¹,

Chandra²

2018

Med-Science

View full text Add to dashboard Cite

show abstract

“…Approximately half of MMP patients have BP180 NC16A antibodies, and the C-terminal domain is targeted [57,58]. MMP patients have been shown to have antibodies that recognize BP230, 97/120 kDa linear IgA bullous dermatosis (LAD) antigen, laminin 332 (laminin 5) and 331 (laminin 6), and type VII collagen [59,60].…”

Section: Mucous Membrane Pemphigoidmentioning

confidence: 99%

Bullous Pemphigoid, Mucous Membrane Pemphigoid and Pemphigus Vulgaris: An Update on Pathobiology

Okon

Werth

2014

Curr Oral Health Rep

View full text Add to dashboard Cite

show abstract

“…The extracellular domain of BP180 is considered to have a number of MMP-reactive antigenic sites of which at least two sites have been identified. One is the non-collagenous 16 a (NC16a) domain located in the upper lamina lucida, and the other is the carboxy-terminus domain at the lamina lucida/lamina densa interface (Bagan et al, 2005;Balding et al, 1996;Bedane et al, 1997;Calabresi et al, 2007;Van den Bergh & Giudice, 2003). The authors evaluated circulating IgG autoantibody specific for BP180NC16a using enzyme-linked immunosorbent assay (ELISA) (Endo et al, 2006a).…”

Section: Mucous Membrane Pemphigoidmentioning

confidence: 99%

“…There is presently no firm correlation between specific clinical phenotypes and the target antigens in MMP patients (Carrozzo et al, 2004;Chan et al, 2002). To date, the most common target antigen associated with MMP is BP180 (Balding et al, 1996;Bedane et al, 1997;Calabresi et al, 2007). The extracellular domain of BP180 is considered to have a number of MMP-reactive antigenic sites of which at least two sites have been identified.…”

Section: Mucous Membrane Pemphigoidmentioning

confidence: 99%